Cartesian tees up Phase 3 mRNA CAR-T study in myasthenia gravis

Lei Lei Wu

News Reporter

Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, suggesting that the therapy is durable beyond the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cartesian tees up Phase 3 mRNA CAR-T study in myasthenia gravis

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

What will pharma's share buyback shopping spree mean for M&A?

Vertex operations chief Stuart Arbuckle to retire

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Carte­sian tees up Phase 3 mR­NA CAR-T study in myas­the­nia gravis

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

Cartesian tees up Phase 3 mRNA CAR-T study in myasthenia gravis

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

What will pharma's share buyback shopping spree mean for M&A?

Vertex operations chief Stuart Arbuckle to retire

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers